Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.
Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.
For more information, please visit Algenex.com.
For further information, please contact:
T: +34 91 452 4941